General Comments / Chat, page-3693

RAC has been on my watchlist for a while - I've never quite pulled the trigger.

The thing that is bugging me: with such a massive clinical trial history, would a highly effective drug ever be lost for 25 years?

One of the articles which comes up on page 1 when Googling 'bistantrene' is this - https://www.epmmagazine.com/pharma-manufacturing-news/why-this-cancer-drug-was-lost-for-25-years/

These are some of the quotes published in the article:

“There’s so much clinical history on this drug, it’s been in 1,800 patients and 46 phase II trials in various cancers,” Race Oncology CEO Peter Molloy told European Pharmaceutical Manufacturer.

“Frankly, when I worked in big pharma, I would have deprioritised [Bisantrene] as well because from big pharma’s perspective it was never going to be a billion-dollar drug,” Molloy states.

As an aside, I'm not surprised Molloy is no longer around given statements like the above!

Comments from the RAC community would be appreciated.